Quicker, Better, Faster Optimising Turn Around Time of Laboratory Results
|
|
|
- Neil Williams
- 6 years ago
- Views:
Transcription
1 Quicker, Better, Faster Optimising Turn Around Time of Laboratory Results Pranitha Ramchuran Regulatory Compliance Manager MTN 003 Regional Meeting Cape Town, South Africa October 2011
2 Outline Organogram Turn around time (TATs) for lab results On-Site Testing Outsourced Testing Rationale for Selection of Outsourced Laboratories CLS and BARC TATs Clinic Flow of Results Challenges and Resolutions
3 LABORATORY ORGANOGRAM PI/ Research Clinician: Sinead Delany-Moretlwe Investigator of Record Thesla Palanee WRHI Laboratory Manager: Mandla Mlotshwa (Back Up) Research Clinician Modulakgotla Sebe; Nina Von Knorring; Kgomotso Morakane Ramasodi; Ogheneruemu Vincent Okwuolise Research Nurses: Angel Nyathi (ATN) Nkgolo Gegana (NMG) Aloysia Makau (AM) Xolelwa Matikinca (XJM) Christine Mapule Maruma (CMM) Regulatory Compliance Manager: Pranitha Ramchuran Clinical Quality Improvement Mentor (CQIM): Lebogang Modise (CLM) Busi Mnguni (BM) Medical Technologist: Lindelwa Nkangane (LN) Medical Technologist: Nomfundo Maduna (Back Up) Colour Key: HIV, Vaginal ph; TV; BV Preg, Urine Dipstick, Wet Mount, Internal QC
4 On-Site Laboratory Testing Laboratory Specimens and Testing Urine Blood Genital SDA: GC/CT BARC (Separation 5ml) Pregnancy Testing: Quidel QuickVue HIV Serology: Abbot Determine OraSure OraQuick Unigold Recombigen Vaginal ph Machery-Nagel Vaginal Gram Stain Vaginal Swab Endocervical Swab MTN Network Lab Urinalysis: Bayer Uristix 4/ Multistix 9 Rapid TV; BV OSOM Trichomonas BV Blue KOH Wet Mount
5 Rationale for Selection of Outsourced Laboratories Service providers identified CLS, BARC (Jhb/Dbn), MRC Central Laboratory (Dbn) Technical protocols developed Past experiences Quickest TATs Financial Penalty Clauses implemented Bioanalytical Research Corporation (BARC): GC/CT Pap Smear: Quicker TAT than MRC Central Laboratory (Dbn) (3-4 days vs 5 days) Quicker TAT than CLS 3 days vs 24 hours Change from conventional smear to liquid based cytology More sensitive Reduces call back of ppts due to inadequate pap smears Reduce time between Scr 1 and Scr 2
6 MTN 003 Outsourced Laboratory Testing Laboratory Specimens and Testing Serology: HBsAg HBsAb HIV Western Blot Haematology: FBC Flow Cytometry: CD4+ T-cells PCR: Viral Load Plasma Archive Urine: SDA: GC/CT Chemistry: AST; ALT; Phosphorous; Creatinine Storage: Vaginal Gram Stain Vaginal Swab Endocervical Swab MTN Network Lab Pap Smear: BD Surepath
7 Discipline Test Turn around time (TAT) Lab Performing the Assay Back-up Lab Serology HBsAg HBsAb 2 working days CLS Jhb National Health Laboratory Services (NHLS) Syphilis 3 working days CLS Jhb NHLS Jhb HIV Western Blot 5 working days National Institute of Communicable Diseases (NICD) NHLS Jhb Haematology Chemistry Full Blood Count AST; ALT; Phosphorous; Creatinine 48 hours CLS Jhb NHLS Jhb 24 hours CLS Jhb NHLS Jhb PCR Viral Load 5 working days NHLS Jhb NHLS Jhb Flow Cytometry CD4+ T-cells 24 hoursweekdays NHLS Jhb NHLS Jhb 72 hoursweekends and public holidays
8 Discipline Test Turn Around Time (TAT) Lab Performing Assay Back-up Lab Molecular Biology SDA GC/CT 3-4 days BARC KZN Lancet Jhb Cytology Pap Smear (BD Surepath Liquid based cytology 24 hours Lancet Cytology Jhb BARC Inhouse Multiple back-ups
9 Outsourced Testing Visit-specific sample requisition forms Volumes If indicated samples Urgent Samples requiring testing Use of URGENT stickers Phone calls and s to CLS/BARC Accrual Phase: Urgent Screening Samples Follow-up Phase: AE Follow-up Seroconvertor Samples Communication with CLS and BARC Equipment and Consumable related delays
10 Flow of Laboratory Results QC of Requisition form Shipping of samples Clinical Review and Management Generation of DCFs Receipt and QC of Results
11 Challenges: Staff Capacity One Clinician Transcription delays Additional clinicians employed Med Tech employed QC systems improved High freq of DCFs Requisition forms Lab Result Reports Shipping Logs DCF Resolution within 24 hours
12 Acknowledgements Lab and Clinical Team at
13
Specimen Management PHRU LAB
Specimen Management PHRU LAB Amanda Mohlala, MT(HPCSA) Perinatal HIV Research Unit University of the Witwatersrand Chris Hani Baragwanath Hospital Johannesburg, South Africa MTN Regional Meeting 2010 PHRU
Prior to site activation the following events were lined up
Pardon Gomani CALENDAR OF EVENTS Prior to site activation the following events were lined up October 2008 Operational walk through in JHB 9 to 17 July study specific training Harare 27 August 09 site specific
MTN 015 SPECIMEN REVIEW. Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe
MTN 015 SPECIMEN REVIEW Gabriel Banda Core Lab Supervisor UNC Project, Lilongwe Review of MTN 015 Study MTN 015 is a multi-site observational cohort study whose study population are women who seroconverted
MTN-038 Laboratory Training. May Beamer, Michele Austin MTN Laboratory Center Magee-Womens Research Institute Pittsburgh, PA
MTN-038 Laboratory Training May Beamer, Michele Austin MTN Laboratory Center Magee-Womens Research Institute Pittsburgh, PA Objectives Resources Specimen Management Overview of Lab testing Supplies Q&A
The laboratory preparation for a new study a pragmatic approach. Compiled by Ken Clarke and Lindiwe Nhlangulela October 2011
The laboratory preparation for a new study a pragmatic approach Compiled by Ken Clarke and Lindiwe Nhlangulela October 2011 We are the Aurum Institute and our laboratory is situated in Klerksdorp in the
QA Processes That Work: Minimizing Errors During On-site Rapid HIV Testing
QA Processes That Work: Minimizing Errors During On-site Rapid HIV Testing Rashika Maharaj MRC HPRU Laboratory Manager MTN Regional Meeting 09 September 2008 HIV and Study Endpoints In most cases, clinical
MTN 005 Laboratory Training. Lorna Rabe MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA
MTN 005 Laboratory Training Lorna Rabe MTN Network Laboratory Magee-Womens Research Institute Pittsburgh, PA Objectives Overview of Lab testing HIV Testing Algorithm Collection and processing of IVR Specimen
SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING
SCREENING AND ENROLLMENT CONSIDERATIONS MTN-038 STUDY-SPECIFIC TRAINING SCREENING AND ENROLLMENT VISITS Screening/ Visit 1 Eligibility Criteria initially assessed Multiple visits, if needed (Split visit)
GSK , 2.0, 18, 2014, DAIDS
Letter of Amendment # 1 to: HPTN 077: A Phase IIa Study to Evaluate the, Tolerability and Pharmacokinetics of the Investigational Injectable HIV Integrase Inhibitor, GSK1265744, in HIV-uninfected Men and
HPTN 035. Laboratory Overview
HPTN 035 Laboratory Overview SSP Laboratory Procedures As the transmission of HIV can occur through contact with contaminated needles, blood, blood product, and vaginal secretions, appropriate blood and
VOICE Screening Part 1 Visit. Operational Walkthrough Johannesburg, South Africa November 2008
VOICE Screening Part 1 Visit Operational Walkthrough Johannesburg, South Africa November 2008 Protocol Requirements Administrative, Behavioral, and Regulatory Procedures Informed consent for screening
Section 12. Laboratory Considerations
Section 12. Laboratory Considerations 12.1 Overview and General Guidance This section contains information on to the laboratory procedures performed in HPTN 035. Some laboratory procedures will be performed
VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS. Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory
VOICE (MTN-003) IT S ALL ABOUT THE ENDPOINTS Edward Livant MT (ASCP), MPH University of Pittsburgh Medical Center MTN Network Laboratory Review of Sample 2 Testing starts here with rapid test (s). Negative
WOMEN'S INTERAGENCY HIV STUDY
WOMEN'S INTERAGENCY HIV STUDY SECTION 6: OVERVIEW OF THE BASELINE VISIT FOR NEW RECRUITS I. 2001/2002 RECRUITS This section provides an overview of the components of the baseline visit for 2001/2002 new
Section 9. Laboratory Considerations
Section 9. Laboratory Considerations This section contains information on the laboratory procedures performed in MTN-027. Table of Contents The page numbers are hyperlinked to the contents below 9.1 Overview
The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa
The Feasibility of HIV Prevention Cohort Studies among Men who have Sex with Men (MSM) in sub-saharan Africa HPTN 075 Protocol Chair: Theo Sandfort New York State Psychiatric Institute and Columbia University
Section 9 Laboratory Consideration
Section 9 Laboratory Consideration 9. Introduction... 9-1 9.1 Overview and General Guidance... 9-2 Table 9-1: Overview of Laboratory Testing Locations, Specimens, and Methods for MTN-034... 9-3 Table 9-2:
ENHANCING LAB PERFORMANCE
ENHANCING LAB PERFORMANCE HPTN Regional Meeting October 19, 2017 Yaw Agyei, MPH, MT (ASCP) Lebah Lugalia, MT (ASCP) HPTN Laboratory Center Johns Hopkins University Hospital Introduction HPTN Lab QA/QC
Section 8. Clinical Considerations
Section 8. Clinical Considerations This section presents information on the clinical procedures performed in MTN-015. Further considerations related to participant safety monitoring and reporting are provided
Section 5. Study Procedures
Section 5. Study Procedures 5.1 Visit Locations... 1 5.2 Eligibility Determination SOP... 1 5.3 Screening Visit... 1 5.3.1 Screening and Enrollment Timeframe... 2 5.3.2 Screening Visit Procedures... 2
SEXUAL HEALTH LAB PRODUCTS
SEXUAL HEALTH LAB PRODUCTS Quick, reliable results for in-office testing Start treatments sooner. Enhance patient outcomes. Long waits for results. Delayed diagnosis and treatment. Cancelled follow-up
Section 6. Participant Follow-up
Section 6. Participant Follow-up This section provides information on requirements and procedures for participant follow-up. 6.1 Study Follow-up Plan and Participant Retention Targets Each enrolled participant
Overview of Enrollment/Initiate Period 1 Visit Procedures
Overview of Enrollment/Initiate Period 1 Visit Procedures What should occur between the Screening and Enrollment visits? Review lab results Chemistries (AST/ALT and Creatinine) CBC with differential and
Section 13. Laboratory Considerations
Section 13. Laboratory Considerations Table of Contents 13.1 Overview and General Guidance 13.2 Specimen Labeling 13.3 Procedures for Specimens That Cannot Be Evaluated 13.4 Use of LDMS 13.5 Documentation
MTN-038 SSP Manual Version November 2018 Section 10 Page 10-1 of 10-30
Section 10. Laboratory Considerations 10. Introduction... 10-2 10.1. Overview and General Guidance... 10-2 10.2. Specimen Labeling... 10-7 10.3. Procedures for Specimens that cannot be evaluated... 10-7
Section 9. Laboratory Considerations
Section 9. Laboratory Considerations 9.1 Overview and General Guidance This section contains information on the laboratory procedures performed in MTN-012/IPM 010. As transmission of HIV and other infectious
Overview of Wet Preps and Gram stains. Lorna Rabe Central Lab Magee-Womens Research Institute Pittsburgh, Pa
Overview of Wet Preps and Gram stains Lorna Rabe Central Lab Magee-Womens Research Institute Pittsburgh, Pa Vaginal Flora A secondary objective of the 035 study is to assess the effectiveness of BufferGel
Medicaid Family Planning Waiver Services CPT Codes and ICD-10 Diagnosis Codes
CPT Code Description of Covered Codes Evaluation and Management 99384FP 99385FP Family planning new visit 99386FP 99394FP 99395FP Family planning established visit 99396FP 99401FP HIV counseling (pre-test)
HIV Basics: Clinical Tests and Guidelines
HIV Basics: Clinical Tests and Guidelines ACTHIV 2010 Zelalem Temesgen MD Mayo Clinic Topics Baseline laboratory evaluation Laboratory monitoring through the continuum of care Patients not on antiretroviral
Pathology Specimen Handling Requirements
CONWAY REGIONAL HEALTH SYSTEM CLINICAL LABORATORY Pathology Specimen Handling Requirements POLICY: Tissue or body fluids, etc. removed or collected during any procedure for purposes of Pathologist examination
TRICHOMONAS VAGINALIS
TRICHOMONAS VAGINALIS What s New: There are no changes to this guideline. Introduction Trichomonas vaginalis (TV) is a flagellated protozoan that is a parasite of the genital tract. Due to site specificity,
Section 5. Study Procedures
Section 5. Study Procedures 5. Introduction 5-1 5.1 Visit Locations... 5-1 5.2 Eligibility Determination SOP... 5-1 5.3 Screening Visit... 5-2 5.3.1 Screening and Enrollment Timeframe... 5-2 5.3.2 Screening
Sexually Transmitted Infections in HSV-2 Seropositive women in Sub- Saharan Africa HPTN 039
Sexually Transmitted Infections in HSV-2 Seropositive women in Sub- Saharan Africa HPTN 039 Ulrika Makuraj, MBBCH University of Witwatersrand Mentor : Sinead Delany-Moretlwe South Africa 17 May 2018 Introduction
MTN 009 Laboratory Logistics
MEDICAL RESEARCH COUNCIL OF SA HIV PREVENTION RESEARCH UNIT MTN 009 Laboratory Logistics RASHIKA MAHARAJ HPRU LABORATORY MANAGER Testing Menu Finger stick Blood Samples HIV Rapid Tests* Venous Blood Samples
9.1 Overview and General Guidance This section contains information on the laboratory procedures performed in MTN-035.
Section 9. Laboratory Considerations 9. Introduction... 9-1 9.1 Overview and General Guidance... 9-1 9.2 Specimen Labeling... 9-4 9.3 Procedures for Specimens that cannot be Evaluated... 9-4 9.4 Use of
H. PYLORI AB, IGG HPYL
H. PYLORI AB, IGG HPYL Specimen Required: 3 ml blood, Serum gel tube Analytical Time: 1 day CPT Code: 86677 HAPTOGLOBIN HAP Specimen Required: 1.5 ml blood, gel tube Reference Range: 30-200 mg/dl CPT Code:
CERTIFICATE OF ACCREDITATION
CERTIFICATE OF ACCREDITATION LANCET KENYA LIMITED UPPERHILL NAIROBI LABORATORY Co. Reg. No.: C168507 Facility Accreditation Number: is a South African National Accreditation System accredited laboratory
How best to structure a laboratory network with new technologies
How best to structure a laboratory network with new technologies Cristina Gutierrez, MD, PhD Uniting to scale up TB care in Central Asia 14 and 15 April 2011 Tashkent, Uzbekistan New laboratory diagnostics
USER GUIDE FOR SPECIMEN COLLECTION
DIAGNOSTIC LAB SPECIMEN COLLECTION GUIDE USER GUIDE FOR SPECIMEN COLLECTION ACM GLOBAL LABORATORIES DIAGNOSTIC SERVICES ACM Global Laboratories offers a comprehensive menu of services that support many
MTN-020. Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012
MTN-020 Jared Baeten, MD PhD Thesla Palanee, PhD On behalf of the ASPIRE team MTN Annual Meeting, Bethesda 21 February 2012 MTN-020 / ASPIRE A Multi-Center, Randomized, Double- Blind, Placebo-Controlled
Refocussing on STI management to impact HIV prevention
Refocussing on STI management to impact HIV prevention Koleka Mlisana Head: Medical Microbiology (UKZN & NHLS) 14 June 2017: SA AIDS Conference NSP 2017 2022 Objectives Goal 1:Accelerate preventioninorder
CERTIFICATE OF ACCREDITATION
CERTIFICATE OF ACCREDITATION In terms of section 22(2) (b) of the Accreditation for Conformity Assessment, Calibration and Good Laboratory Practice Act, 2006 (Act 19 of 2006), read with sections 23(1),
MTN-020 and IPM 027 and the MTN-020 DSMB. Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012
MTN-020 and IPM 027 and the MTN-020 DSMB Jared Baeten, MD PhD Thesla Palanee, PhD ASPIRE Protocol Team Meeting 22 February 2012 Developing a range of options for antiretroviral-based HIV prevention Pill
Sexually Transmitted Infections in the Adolescent Population. Abraham Lichtmacher MD FACOG Chief of Women s Services Lovelace Health System
Sexually Transmitted Infections in the Adolescent Population Abraham Lichtmacher MD FACOG Chief of Women s Services Lovelace Health System STI in the Adolescent High school students nationwide, 34.2% were
N ational STI M icrobiological Surveillance Programme David A. Lewis FRCP(UK) PhD
N ational STI M icrobiological Surveillance Programme David A. Lewis FRCP(UK) PhD Sexually Transmitted Infections Reference Centre National Institute of Communicable Diseases (NHLS) South Africa Mission
Anti-Infective Clinical Trials
Anti-Infective Clinical Trials The extensive clinical training and experience of our infectious disease staff places us in a unique position to fully appreciate the requirements of our clients conducting
TEST LIST SAMPLE REQUIREMENT. 1 ml serum None
ALBUMIN TEST NAME ALKALINE PHOSPHATASE ALLERGY PROFILE, FOOD 30 allergens ALLERGY PROFILE, INHALANT 30 Allergens ALT AMYLASE ANA ANTI- TG ANTI-GLIADIN IGG ANTI-GLIADIN IGA ANTI-HBS ANTI-HCV ANTI-TPO APOLIPOPROTEIN
Integrating HIV Screening Into
MaxiMizing Third ParTy reimbursement for hiv TesTing Integrating HIV Screening Into Title X Services IntroductIon HIV screening services are a core family planning service, and all individuals aged 13-64
Processing of female genital specimens at Labtests and Northland Pathology Laboratory
Consultation document Processing of female genital specimens at Labtests and Northland Pathology Laboratory Author: Dr Arlo Upton Page 1 of 9 Date: 07/03/16 Table of contents 1. INTRODUCTION...3 2. CURRENT
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites. Updated: February 2018 Cicely Richard Office of HIV/AIDS
Unigold Recombigen HIV 1/2 Training for HIV Testing Sites Updated: February 2018 Cicely Richard Office of HIV/AIDS Updated: February 2018 Cicely Richard Office of HIV/AIDS UNIGOLD RECOMBIGEN HIV 1/2 TRAINING
IP Lab Webinar 8/23/2012
2 What Infection Preventionists need to know about the Laboratory Anne Maher, MS, M(ASCP), CIC Richard VanEnk PhD, CIC 1 Objectives Describe what the laboratory can do for you; common laboratory tests
CERTIFICATE OF ACCREDITATION
CERTIFICATE OF ACCREDITATION In terms of section 22(2) (b) of the Accreditation for Conformity Assessment, Calibration and Good Laboratory Practice Act, 2006 (Act 19 of 2006), read with sections 23(1),
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 4 Immunology MLE-M1 Total Commitment to Education and Service Provided by ACP, Inc. Table of Contents Evaluation Criteria...
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 3 Total Commitment to Education and Service Provided by ACP, Inc. Immunology MLE-M2 Table of Contents Evaluation Criteria...
M.D.IPA, M.D.IPA Preferred, Optimum Choice and Optimum Choice Preferred STAT Laboratory List Revised Jan. 5, 2017
M.D.IPA, M.D.IPA Preferred, Optimum Choice and Optimum Choice Preferred STAT Laboratory List Revised Jan. 5, 2017 If laboratory results are required on a STAT basis, the designated commercial medical laboratory
Follow-up Visit Procedures MTN-009
Follow-up Visit Procedures MTN-009 General Overview MTN-009 follow-up visits are only required for participants who are found to be HIV infected These participants will have a minimum of two follow-up
Testing Kits. Pregnancy Test Kits. Hepatitis Test Kits. HIV - 1 & 2 Test Kits
Pregnancy Test Kits Sr Item Name Store At Pack Size 1 hcg Card Test 2 hcg Card Test 3 Hope hcg Card Test 4 hcg Dipstick Test 5 LH Surge Card Test 5 T 6 LH Surge Card Test 10 T Hepatitis Test Kits 7 HCsAg
ONLINE SUPPLEMENTARY MATERIALS: FILE 1
ONLINE SUPPLEMENTARY MATERIALS: FILE 1 Clinical care pathways using chlamydia and gonorrhoea tests are evolving: point of care nucleic acid amplification tests may reduce genitourinary medicine service
Section 6. Participant Follow-up
Section 6. Participant Follow-up Table of Contents 6.1 Study Follow-up Plan and Participant Retention Targets 6.2 Types of Follow-up Visits 6.3 Follow-up Visit Locations 6.4 Follow-up Visit Procedures
TEST REQUEST INFORMATION- VIROLOGY
Chlamydia/ Gonorrhea Nucleic Acid Amplification VC75 Qualitative Nucleic Acid Amplification SPECIMEN: Genital swab or first catch urine CONTAINER:GEN-PROBE APTIMA 2 Combo swab transport tube or urine transport
HEALTH ASSESSMENT FOR NEW ZEALAND VISA APPLICANTS
INFORMATION SHEET HEALTH ASSESSMENT FOR NEW ZEALAND VISA APPLICANTS Health assessments of New Zealand visa applicants are conducted by the International Organization for Migration (IOM) on behalf of Immigration
Management of NGU (Non-gonococcal urethritis)
Management of NGU (Non-gonococcal urethritis) First line Doxycycline 100mg po bd for 7 days (contra-indicated in pregnancy) Alternative regimens Azithromycin 1G po stat Azithromycin 500mg po stat, then
Transfusion Medicine (Comprehensive, Limited) J, J1
www.cap.org Transfusion Medicine Analytes/procedures in bold type are regulated for proficiency testing by the Centers for Medicare & Medicaid Services (CMS). Transfusion Medicine (Comprehensive, Limited)
SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: MTN-004 DAIDS Document ID 10492
SUMMARY OF CHANGES INCLUDED IN THE FULL PROTOCOL AMENDMENT OF: MTN-004 DAIDS Document ID 10492 Phase 1 Study of the Safety and Acceptability of 3% w/w SPL7013 Gel (VivaGel ) Applied Vaginally in Sexually
Sexual health screening
Sexual health screening This guideline provides screening recommendations that are based on anatomy and is inclusive of genderaffirming surgeries and hormone therapy. All patients should be screened according
Balancing investment in point of care diagnostics versus laboratory testing in low resource settings. June 28, 2011
Balancing investment in point of care diagnostics versus laboratory testing in low resource settings Workshop on TB and HIV Diagnostics Workshop on TB and HIV Diagnostics June 28, 2011 Complexity Delivery
Rapid Point-of-Care Tests for STIs: needs, progress, challenges
Rapid Point-of-Care Tests for STIs: needs, progress, challenges Ranmini Kularatne Centre for HIV and STIs National Institute for Communicable Diseases National Health Laboratory Service South Africa Nov
CDC Laboratory Update
CDC Laboratory Update Chlamydia and Gonorrhea Laboratory Guidelines Overview of the APHL / CDC STD Steering Committee Laboratory Recommendations for the Detection of Chlamydia trachomatis, Neisseria gonorrhoeae
Robert G. Gish MD UC San Diego
Robert G. Gish MD UC San Diego The Pipeline of HIV-Related Point-Of- Care Tests is Growing Viral detection Examples: 2012 2013 2014 2015 2016 2017 CD4 test Examples: 2009 2010 2011 2012 2013 0 2014 Evidence
Specimen Submission Guide
Specimen Submission Guide 5802 Wright Drive Loveland, CO 80538 Phone (970) 212-0530 Fax (970) 212-0553 Toll Free (800) 920-6227 1 Table of Contents Gynecologic Cytology and Affiliated Molecular Testing
M E D I C A L L A B O R A T O R Y
M E D I C A L L A B O R A T O R Y E V A L U A T I O N PARTICIPANT SUMMARY 2 0 1 1 Total Commitment to Education and Service Provided by ACP, Inc. Immunology MLE M1 Table of Contents 2011 Evaluation Criteria...
CERTIFICATE OF ACCREDITATION
CERTIFICATE OF ACCREDITATION LANCET LABORATORIES Registration No: 4120108883 Facility Accreditation Number: MED 006 is a SADCAS accredited Medical Laboratory provided that all SADCAS conditions are complied
Med Chem 535P ~ Diagnostic Medicinal Chemistry. General Comments
Med Chem 535P ~ Diagnostic Medicinal Chemistry General Comments Most blood chemistry and serology assays are performed automatically. Larger clinical laboratories often use sophisticated analyzers that
New Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility
New Molecular Diagnostic Assays for Solana Performance Assessment, Workflow Analysis, and Clinical Utility Gerald A. Capraro, Ph.D., D(ABMM) Director, Clinical Microbiology Carolinas Pathology Group Atrium
The new Cervical Screening Test for Australian women: Louise Farrell
The new Cervical Screening Test for Australian women: Louise Farrell Outline and explain the changes to the National Cervical Screening Program due to commence in Dec 2017 LEARNING OBJECTIVES FOR TODAY
Cost drivers in Microbiology/Serology laboratory testing: some perspectives
Cost drivers in Microbiology/Serology laboratory testing: some perspectives Dr S Hajee Consultant Microbiologist VERIPATH 1 introduction Consensus on the need and desirability to reduce the money spent
Medical Laboratory Accreditation Programme
Client Client Number 121 Address PO Box 6064, Dunedin North, Dunedin, 9059 Plunket House, 472 George Street, North Dunedin, Dunedin, 9016 Telephone 03 477-6981 Fax 03 477-9160 Authorised Representative
Evaluation of VACUETTE Urine CCM Tubes for Urine Strip Testing
Evaluation of VACUETTE Urine CCM Tubes for Urine Strip Testing Background The VACUETTE Urine is for the collection, transport and storage of urine samples for urine culture and urinalysis in the laboratory.
Lymphogranuloma Venereum (LGV) Surveillance Project
Lymphogranuloma Venereum (LGV) Surveillance Project Lymphogranuloma venereum (LGV) is a systemic, sexually transmitted disease (STD) caused by a type of Chlamydia trachomatis (serovars L1, L2, L3) that
Specimen Submission Guide
Specimen Submission Guide 5802 Wright Drive Loveland, CO 80538 Phone (970) 212-0530 Fax (970) 212-0553 Toll Free (800) 920-6227 1 Table of Contents Gynecologic Cytology and Affiliated Molecular Testing
An Update on FACTS 001. Prof Helen Rees FACTS Protocol Chair
An Update on FACTS 001 Prof Helen Rees FACTS Protocol Chair FACTS 001 A Phase III, Multi-Centre, Randomised Controlled Trial to Assess the Safety and Effectiveness of the Vaginal Microbicide 1% Tenofovir
Clinical Management Guidelines 2012
Central American Course Monitoring and Evaluation for HIV/AIDS Policy and Program Management 1 2 3 4 Module 1 Unit 1 Clinical Management Guidelines 2012 National TB, HIV/AIDS & other STIs Programme Ministry
Guidelines for Specimen Submission to Pathology Laboratory
به نام خدا Guidelines for Specimen Submission to Pathology Laboratory Pre-analytic phase 1. Specimen identification 2. Adequacy of clinical history 3. Specimen fixation 4. Specimen delivery 5. Accessioning
Specimen Collection & Handling Instructions HUMAN PAPILLOMAVIRUS (HPV) COLLECTION IN SUREPATH
HUMAN PAPILLOMAVIRUS (HPV) COLLECTION IN SUREPATH NOTE: HPV TESTING IS NOT FUNDED BY MOHLTC Patient payment of $90.00 is required HPV testing can be used to refine the management of women over the age
MTN-038 Clinical Considerations. Site Specific Training 11 Sept 2018
MTN-038 Clinical Considerations Site Specific Training 11 Sept 2018 Overview Medical and Menstrual History Physical and Pelvic Exams STI/RTI/UTIs Con Meds Contraception Prohibited Meds and Practices Product
Standard Operating Procedure
Standard Operating Procedure 1. Definitions Section: Laboratory Version No. 1.2 Initials: AD Title: 2.0 Testing Algorithm Revision Date: 01 Sep 2011 1.1 SOP: Standard Operating Procedure 1.2 CRF: Case
Safety Profile of Viread and Truvada. Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008
Safety Profile of Viread and Truvada Ian McGowan, MD PhD FRCP Cape Town MTN Regional Meeting September, 2008 Overview Safety assessment in drug development Physiology 101 Renal Bone Liver Safety profile
Corporate Medical Policy
Corporate Medical Policy Multitarget Polymerase Chain Reaction Testing for Diagnosis of File Name: Origination: Last CAP Review: Next CAP Review: Last Review: multitarget_polymerase_chain_reaction_testing_for_diagnosis_of_bacterial_vaginosis
HIV and PEP. LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED
HIV and PEP LTC Rose Ressner WRNMMC ID staff Oct 2014 UNCLASSIFIED Disclaimer The views expressed in this presentation are those of the speaker and do not reflect the official policy of the Department
Pathology the missing link in global health care delivery Quentin Eichbaum
Pathology the missing link in global health care delivery Quentin Eichbaum MD, PhD, MPH, MFA, MMHC, JD, BSc(Med)(Hons), BA(Hons), FCAP, FASCP Professor or Pathology, Microbiology and Immunology Professor
Physician Office Laboratory Tests
Important Change Effective March 1, 2018 Physician Office Laboratory Tests Molina Healthcare of Michigan has updated its list of payable laboratory tests that may be performed in a physician s office.
Health Screening for Nanyang Technological University (NTU)
Health Screening for Nanyang Technological University (NTU) Health screening packages are offered at corporate rates to NTU staff and dependents at the indicated clinics. Please refer to this document
Make the BD FocalPoint GS Imaging System your guide in cervical cytology screening. Computer-guided screening
Computer-guided screening Liquid-based cytology Immuno-chemistry Make the BD FocalPoint GS Imaging System your guide in cervical cytology screening Directs your attention to slides most likely to contain
What s New. Vaginal Discharge Protocol. History
What s New Information has been added on interpreting vaginal scoring system and AV scores. Vaginal Discharge Protocol History Low risk STI PLUS Typical BV or VVC history AND No symptoms of PID High risk
Siemens Healthcare Diagnostics
Siemens Healthcare Diagnostics A Global Industry Leader 3.7bn in sales More than 14,500 employees Serving 30,000 customers in more than 120 countries Approximately 244,000 instruments installed R&D spending
Nothing to disclose.
Update on Diagnosis and Treatment Lisa Winston, MD University of California, San Francisco/ Zuckerberg San Francisco General Nothing to disclose. 1 This talk will be a little depressing Rising incidence
AccuSet HIV-1/2 Performance Panel
OVERVIEW AccuSet HIV-1/2 (0800-0380) is a 13-member validation panel of undiluted, naturally occurring plasma samples (1 vial per member, 1.0 ml per vial). Panel members represent bleeds from multiple
Remind me, what s an STI? And why are they relevant to me?
Remind me, what s an STI? And why are they relevant to me? Sexually transmitted infections (STIs) are often caused by bacteria or viruses and are typically (though not always) passed from one person to
Reliable, cost-effective CT/GC testing For labs with low to medium throughput needs. The BD ProbeTec ET System
Reliable, cost-effective CT/GC testing For labs with low to medium throughput needs The BD ProbeTec ET System The demand is there. The system is here. Now your lab can run up to 15,000 samples a year reliably